EarningsQ2 2026 Earnings Report

Ginkgo Bioworks Holdings (DNA) Q2 2026 Earnings Report

0 Followers

Previous Report: Q1 2026

MX:DNA Q2 2026 EPS Results

Actual EPS-$13.62

Consensus EPS-$16.25

Beat/MissBeat by +$2.63

One Year Ago EPS-$19.98

MX:DNA Q2 2026 Revenue Results

Actual Revenue$366.05M

Expected Revenue$436.76M

Beat/MissMissed by -$70.72M

YoY Revenue Growth-59.37%

Earnings Announcement Details

QuarterQ2 2026

Date08/05/2026

TimeAfter Close

Conference CallWednesday, August 5, 2026

MX:DNA Upcoming Earnings

Ginkgo Bioworks Holdings's next earnings date is estimated for November 16, 2026, based on past reporting schedules.

Q2 2026 Earnings Call Audio

MX:DNA Q2 2026 Earnings Call

0:00 / 0:00

Q2 2026 Earnings Slide Deck

Q2 2026 Earnings Call Summary

Q2 2026

Earnings Call Date:Aug 05, 2026|

% Change Since:

Earnings Call Sentiment|Neutral

The call balanced significant strategic and operational progress with near-term financial headwinds. Positives include major academic and national lab contracts, rapid expansion and scale demonstration of Nebula, a competitive ADME product with strong price/performance and a solid cash position plus a reduced long‑term Google Cloud commitment. Negatives include steep year‑over‑year revenue declines, wider GAAP losses and worse adjusted EBITDA in Q2, elevated quarter‑specific cash burn and ongoing excess lease costs. Management emphasizes cost discipline, a shift toward investing in autonomous labs and predictable cash burn guidance for 2026, but revenue recognition timing for automation deals and the need to further mature operations create near‑term uncertainty.

Company Guidance

Management reaffirmed full‑year 2026 cash‑burn guidance of $125 million to $150 million while saying they expect further cash‑burn improvement in H2; the company enters H2 with $302 million of cash and cash equivalents plus $87 million of restricted cash. Key Q2 and H1 metrics cited: Q2 revenue $20 million (down 48% YoY) and H1 revenue $40 million (down 49% YoY; ~42% decline ex. $7.5 million non‑cash BiomEdit item), R&D $30 million in Q2 (down 4% YoY), G&A $12 million in Q2 (down 26% YoY), net loss from continuing operations of $57 million in Q2 (vs $53 million prior year), and adjusted EBITDA of negative $36 million in Q2 (vs negative $25 million), which includes $14 million of excess‑lease carrying costs (up from $12 million). Cash‑burn was $45 million in Q2 and $93 million in the first half (down 3% from $96 million), noting a $17 million ATM raise (excluded from cash‑burn) and a $14 million Google Cloud payment in Q1 that raised near‑term burn; the Google Cloud reset reduced future minimum commitments by more than $100 million and extended the term from 3 to 6 years.

Strategic NSF and Academic Wins

Selected to build autonomous labs for MIT, Caltech, University of Maryland and Northwestern (NSF-funded or separate grant for MIT), positioning Ginkgo as a supplier of campus cloud/autonomous labs and training the next generation of scientists.

Nebula Expansion and Operational Scale

Nebula autonomous lab in Boston expanded to 105 RACs (added ~50 RACs in ~3 weeks); system runs 24/7, handles ~30 unique protocols/day (over 100 protocol runs counting duplicates), and demonstrates rapid productized deployment capability.

Competitive CRO Offering — ADME-One Launch

Launched ADME-One service (~6 weeks prior) offering a 5-assay ADME panel at $199 vs typical Western CRO $2,000–$5,000 and Chinese CRO $1,000–$2,500 — roughly a ~90% price advantage; internal and external validation (including LOPAC dataset) shows good agreement with industry peers.

Improved Operating Expense Discipline

Q2 2026 R&D decreased 4% YoY (from $31M to $30M) and G&A decreased 26% YoY (from $16M to $12M), driven primarily by restructuring actions substantially concluded at end of 2025.

Strong Liquidity Position and Contractual Improvements

Cash and cash equivalents of $302M plus $87M restricted cash; renegotiated Google Cloud commitment (paid $14M in Q1) reduced future minimum commitments by >$100M and extended term from 3 to 6 years, improving future cash outlook.

Reaffirmed Cash Burn Guidance

Management reaffirmed 2026 cash burn guidance of $125M–$150M, highlighting focus on cost efficiency while investing in AI, robotics and autonomous labs.

Capital Raised via ATM

Raised $17M in Q2 through at-the-market equity program (proceeds excluded from cash burn), adding to liquidity.

MX:DNA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change
Nov 16, 2026	2026 (Q3)	-18.31 / -	-26.333	―
Aug 05, 2026	2026 (Q2)	-16.25 / -13.62	-19.977	31.82% (+6.36)
May 07, 2026	2026 (Q1)	-21.99 / -25.24	-30.51	17.26% (+5.27)
Feb 26, 2026	2025 (Q4)	-26.42 / -25.61	-36.321	29.50% (+10.71)
Nov 06, 2025	2025 (Q3)	-22.54 / -26.33	-19.614	-34.26% (-6.72)
Aug 07, 2025	2025 (Q2)	-28.46 / -19.98	-79.907	75.00% (+59.93)
May 06, 2025	2025 (Q1)	-27.86 / -30.51	-58.114	47.50% (+27.60)
Feb 25, 2025	2024 (Q4)	-27.31 / -36.32	-79.907	54.55% (+43.59)
Nov 12, 2024	2024 (Q3)	-49.54 / -19.61	-116.228	83.13% (+96.61)
Aug 08, 2024	2024 (Q2)	-56.26 / -79.91	-65.378	-22.22% (-14.53)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed